ClinicalTrials.gg
Not yet recruitingNCT07941895Updated Nov 17, 2026

Biphasic Effect of Alcohol on Pain

A Phase 2 interventional study of Alcohol (IV) and Saline (0.9%, sterile, for infusion) in Alcohol Use, Chronic Low-back Pain (cLBP) and Alcohol Use Disorder (AUD), sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionAlcohol Drinking(the registry's first term)UnverifiedIs this wrong?Alcohol Drinking is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Yale University · Phase 2, Interventional, and Basic science

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

Alcohol's effects on pain are biphasic and depend on blood alcohol concentration; as concentration rises (i.e., ascending limb) and then falls (i.e., descending limb), alcohol produces distinct, time-dependent effects on pain. However, the biphasic effects of alcohol among individuals with chronic pain and alcohol use disorder, and the extent to which these effects may motivate alcohol consumption, remain poorly understood. The primary objective of the proposed study is to quantify alcohol-clamp-induced group differences in the net effects of alcohol on pain threshold and tolerance.

Read the detailed description

Alcohol use disorder (AUD) and chronic pain (CP) are major public health challenges in the United States. AUD is the third leading preventable cause of death, and CP affects up to 116 million Americans. Chronic low back pain alone is the leading global cause of disability. Together, these conditions impose an economic burden exceeding $750 billion annually. People with AUD are significantly more likely to experience moderate to severe pain (43-75% vs. 18% in the general population), and unrelieved pain can worsen alcohol craving and increase use of analgesics that carry addiction risk, such as opioids.

The relationship between AUD and CP operates as a self-reinforcing cycle, where individuals use alcohol for pain relief but overtime develop a tolerance to its effects, requiring increasing amounts to achieve the same analgesic effects. Subsequently, when alcohol use is reduced or stopped, withdrawal-driven hyperalgesia emerges, further increasing pain sensitivity. This creates a negative reinforcement trap: individuals drink not primarily for the initial euphoria or analgesia, but to escape the rebound pain that alcohol itself has exacerbated. Over time, this cycle alters nociceptive processing, leading to heightened pain sensitivity, impaired pain inhibition, and greater alcohol craving. Consistent with negative-reinforcement models, 72% of individuals with AUD report drinking for pain relief at least sometimes, and 42.4% at least half the time.

Despite their frequent co-occurrence, research has largely examined AUD and CP separately. Prior work that was done in healthy persons, rather than in persons with AUD, had limited control of exposure due to the high variability in oral alcohol pharmacokinetics, and missed alcohol-comorbidity interactions. This study addresses these gaps by enrolling persons with AUD, CP, and AUD+CP alongside healthy controls, using a computer-controlled IV alcohol clamp to eliminate pharmacokinetic variability to rigorously examine the pain-alcohol relationship.

02

Conditions studied

  • Alcohol Use
  • Chronic Low-back Pain (cLBP)
  • Alcohol Use Disorder (AUD)
  • Quantitative Sensory Testing
  • Pain Alleviation

Browse trials for

Keywords

  • Negative Reinforcements
  • Alcohol consumption
  • Alcohol expectancy
  • Intravenous infusion procedures
  • Pain measurement
  • Alcohol Use Disorder
  • Chronic low back pain
03

In context

Alcohol Drinking Unverified

702 studies on the registry are indexed under Alcohol Drinking; 134 are open to participants now.

This study's planned enrollment of 132 is close to the median of 124 across 608 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

Yale University is the lead sponsor of 1,773 studies on the registry; 297 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Compared within Alcohol Drinking, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Ability to provide in English.
  • 2. Provision of signed and dated informed consent form.
  • 3. Stated willingness to comply with all study procedures and availability for the duration of the study.
  • 4. Male and female participants aged 21 to 65 years.
  • 5. For women of , i.e., not surgically sterilized (tubal ligation/hysterectomy) or not (no menstrual period for greater than 12 months): (a.) Must have a negative urine pregnancy test at screening and immediately before test sessions. (b.) Must be willing to use a medically acceptable and effective method while participating in the study.
  • 6. Have no , in the judgment of the SI/study physician, for study participation (based on self-reported medical history and physical examination)
  • 7. Safe transportation plan after the dosing session (e.g., a designated drive, or pre-arranged transportation).

For AUD groups (encompassing persons with AUD-only and persons with AUD+CP):

  • 1. Meet criteria for alcohol use disorder.
  • 2. Have experienced at least one heavy drinking episode in the past 30 days (defined as consuming more than four standard drink units (SDU) for men and more than three SDU for women).

For CP groups (encompassing persons with CP-only and persons with AUD+CP):

- 1. Have high-impact, non-cancer low back pain that has persisted for at least three months, occurs on most days, and limits life or work activities.

For healthy individuals:

  • 1. No current or lifetime DSM-5 diagnosis of substance use disorder (excluding tobacco use disorder).
  • 2. Alcohol use within normal NIAAA-defined limits (i.e., 14 or fewer drinks per week for men or 7 or fewer drinks per week for women; with no binge drinking episodes in the past 3 months).
  • 3. No chronic pain as defined for CP groups.
  • 4. No regular use of pain medications or psychotropic medications.

Exclusion criteria

Exclusion Criteria:

  • 1. Meeting criteria for any substance use disorders other than alcohol and/or tobacco use disorder within the past year.
  • 2. Currently seeking treatment for AUD.
  • 3. Currently experiencing alcohol withdrawal, defined as a Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) score greater than 8.
  • 4. Recent history of complicated alcohol withdrawal, alcohol withdrawal seizures, or delirium tremens.
  • 5. Current physiological alcohol dependence requiring a higher level of care (e.g., detox) as determined by the study physician conducting a physical examination.
  • 6. Current bipolar disorder, primary psychotic disorders, or mood disorders with psychotic features.
  • 7. Current suicidal ideation, intent, or plan as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS).
  • 8. Females who are pregnant, nursing, or planning to become pregnant during study participation.
  • 9. Positive pregnancy test or lack of measures in women of .
  • 10. Clinically major medical disorders including: liver disease, heart disease, cardiac disease, or other medical conditions that the SI or study physician deems for participation.
  • 11. medical conditions including hepatic ascites ( greater than 10% above the [ULN], liver function tests [LFT] greater than 3x ULN), or renal impairment as measured by BUN/Creatinine.
  • 12. Neurological conditions that may change the response to nociceptive stimuli (e.g., stroke, neuropathy), as evidenced by a neuro-sensory examination.
  • 13. Contraindications for exposure to nociceptive stimuli, such as untreated hypertension.
  • 14. Major neurocognitive disorders (e.g., dementia, delirium, amnestic) precluding participation, as evidenced by a clinical examination.
  • 15. Currently taking the following medications: (a.) Opioids; (b.) Benzodiazepines; (c.) Medications for alcoholism; (d.) Psychotropic medications that promote sedation, including sedative/hypnotics, barbiturates, sedative antidepressants, and triptans; (e.) Antihypertensive medications; (f.) Centrally acting alpha-2 adrenergic agonists or alpha-1 adrenergic antagonists prescribed for any indication.
  • 16. For non-opioid analgesics (e.g., NSAIDs, gabapentinoids, cyclobenzaprine), participants must meet the following medication stabilization criteria: no start/stop or 25% or greater dose change within 14 days before the first test session, and no as-needed use within 12 hours before each test session.
  • 17. Positive urine drug screen for illicit substances prior to the start of each test session.
  • 18. Positive THC saliva assay and/or urine THC concentration greater than 50 ng/mL prior to the start of each test session assessed using a quantitative point-of-care urine 11-nor-9-carboxy-THC concentration test.
  • 19. Participation in a clinical trial of a pharmacological agent within 30 days prior to screening.
  • 20. Any other condition that, in the investigator's judgment, would compromise safety or ability to complete the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Healthy individuals

    Participants whose alcohol use falls within normal NIAAA defined limits and do not experience chronic low back pain.

    Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)

  • Experimental
    Alcohol Use Disorder (AUD)-only

    Participants meeting DSM-5 criteria for alcohol use disorder who do not experience chronic low back pain.

    Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)

  • Experimental
    Chronic Pain (CP)-only

    Participants who have high-impact, non-cancer low back pain that has persisted for at least three months whose alcohol use falls within normal NIAAA defined limits.

    Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)

  • Experimental
    AUD+CP

    Participants meeting DSM-5 criteria for AUD and experience high-impact, non-cancer low back pain that has persisted for at least three months.

    Drug: Alcohol (IV) · Drug: Saline (0.9%, sterile, for infusion)

Interventions

  • DrugAlcohol (IV)

    Two 1 liter IV bags containing 6% alcohol will be administered to participants to achieve 0.1 BrAC.

  • DrugSaline (0.9%, sterile, for infusion)

    The placebo will consist of saline, administered intravenously using the same IV bags, infusion equipment, and procedures as the alcohol.

06

What researchers measure

Primary outcomes

  1. Net effect of alcohol on heat pain threshold (HPTh), compared across four diagnostic groups

    Heat pain threshold (HPTh) is the temperature (°C) at which a heat stimulus first becomes painful. Scores are baseline-adjusted alcohol-minus-placebo differences in HPTh. Net effect = ascending-limb increase minus descending-limb decrease. Ascending-limb increase: the maximum rise in HPTh from baseline to BrAC 0.10 g/dL. Descending-limb decrease: the maximum drop in HPTh from BrAC 0.10 g/dL to 0.02 g/dL. Positive values indicate net analgesia; negative values indicate net hyperalgesia. Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  2. Net effect of alcohol on heat pain tolerance (HPTol), compared across four diagnostic groups

    Heat pain tolerance (HPTol) is the highest temperature (°C) the participant tolerates, measured right after HPTh. Scores are baseline-adjusted alcohol-minus-placebo differences in HPTol. Net effect = ascending-limb increase minus descending-limb decrease. Ascending-limb increase: the maximum rise in HPTol from baseline to BrAC 0.10 g/dL. Descending-limb decrease: the maximum drop in HPTol from BrAC 0.10 g/dL to 0.02 g/dL. Positive values indicate net analgesia; negative values indicate net hyperalgesia. Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

Secondary outcomes

  1. Mapping pain modulatory mechanisms of the transition from analgesia to hyperalgesia as measured by Conditioned Pain Modulation (CPM)

    CPM will serve as an index of descending pain inhibition, measured as the reduction in pain perception to a test stimulus when delivered simultaneously with a conditioning stimulus. Seven heat stimuli (46.5°C, 4 sec duration, 15-sec inter-stimulus interval) will be delivered to the dominant-hand thenar eminence. During the heat stimuli, a contralateral conditioning cold stimulus (5°C for 40 sec) will be applied to the ventral forearm. Participants will continuously rate pain on a 0 to 100 mm computerized visual analog scale (Co-VAS), where higher ratings mean more pain. CPM will be defined as the peak unconditioned minus the peak conditioned Co-VAS pain rating (i.e., the maximum rating to the heat test stimuli without versus with cold conditioning), with higher values indicating stronger descending inhibition. CPM ranges from minus 100 to 100; higher is better. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  2. Mapping pain modulatory mechanisms of the transition from analgesia to hyperalgesia as measured by Temporal Summation of Pain (TSP)

    TSP will serve as an index of pain facilitation, reflecting the wind-up of pain perception in response to repeated noxious stimuli. Ten heat pulses (46.5°C, 0.5-sec duration, 2.5-sec inter-pulse interval) will be delivered while participants continuously rate their pain on a 0 to 100 mm computerized visual analog scale (Co-VAS), where higher ratings mean more pain. TSP will be quantified as the area under the curve (AUC) of the Co-VAS ratings across the 10 pulses, with higher values indicating greater wind-up of pain. The lowest possible value is 0; higher values mean a worse outcome. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

Other outcomes

  1. Change in baseline expectancy as assessed by the Expectancy of Alcohol Analgesia (EAA) questionnaire

    The Expectancy of Alcohol Analgesia (EAA) questionnaire is a validated 5-item self-report scale designed to measure an individual's belief or expectation that drinking alcohol will reduce or help them cope with physical pain. Each item is rated on a 10-point scale ranging from 0 ('completely/extremely unlikely') to 9 ('completely/extremely likely'). Scores are calculated by summing the ratings of each item, with higher scores reflecting stronger expectancies. Total scores range from 0 to 45; higher scores are neither a better nor a worse outcome. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  2. Perceived pain relief of alcohol administration as assessed by a 100-mm visual analog scale (VAS)

    Perceived pain relief will be assessed at each BrAC window with a single 100-mm visual analog scale (VAS) (anchors "no pain relief" to "complete pain relief"). Scores range from 0 to 100; higher scores mean more pain relief (a better outcome). Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  3. Alcohol-induced changes in pro- and anti-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta, IL-10) versus placebo

    To investigate peripheral neuroimmune mechanisms underlying alcohol's effects venous blood samples will be collected at three BrAC matched windows. Pro-inflammatory (IL-6, TNF-α, IL-1β) and anti-inflammatory (IL-10) cytokines will be assayed in duplicate using multiplex immunoassay panels for Ella (Bio-Techne). Duplicates are averaged and intra/inter-assay coefficient of variation is set at less than 10%. These cytokines were selected as they are elevated in both CP and AUD and show rapid changes in response to alcohol exposure. All four are reported in picograms per milliliter (pg/mL). Higher values of IL-6, TNF-α and IL-1β mean more inflammation; higher IL-10 means more anti-inflammatory activity. Measured at baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.02 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  4. Alcohol-induced sedation as assessed by a 100-mm visual analog scale (VAS)

    Alcohol-induced sedation will be assessed at each BrAC window with a single 100-mm visual analog scale (VAS) (anchors "not at all sedated" to "extremely sedated"). Scores range from 0 to 100; higher scores mean more sedation (a worse outcome). Measured at five breath alcohol concentration (BrAC) windows in each session: baseline (0.00 g/dL), rising 0.04 and 0.10 g/dL, and falling 0.04 and 0.02 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  5. Alcohol-related affect as assessed by the Brief Biphasic Alcohol Effects Scale (B-BAES) stimulation subscale

    The Brief Biphasic Alcohol Effects Scale (B-BAES) is a self-report questionnaire assessing the acute stimulant and sedative properties of alcohol across the ascending and descending BrAC phases. For this study only the stimulation subscale will be assessed. The stimulation subscale includes 3 items measuring activation, arousal, and positive-like activation. Higher scores indicate stronger feelings of reward, sociability, and euphoria while BrAC is rising. Each item is rated on an 11-point scale ranging from 0 ('Not at all') to 10 ('Extremely'). The subscale score is calculated by summing the ratings of the respective items. Subscale scores range from 0 to 30; higher scores are neither a better nor a worse outcome. Measured at three BrAC windows in each session: baseline (0.00 g/dL), rising 0.10 g/dL and falling 0.04 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  6. Alcohol related craving as assessed by the Alcohol Urge Questionnaire (AUQ)

    The Alcohol Urge Questionnaire (AUQ) is an 8-item self-report questionnaire designed to measure a person's acute, real-time desire or urge to drink alcohol ("right now"). Each item is rated on a 7-point Likert scale ranging from 1 ("strongly disagree") to 7 ("strongly agree"). Scores are calculated by summing the ratings of each item, with higher scores reflecting a stronger, more acute urge to consume alcohol. Total scores range from 8 to 56; higher scores mean a worse outcome. Measured at three BrAC windows in each session (baseline 0.00 g/dL, rising 0.10 g/dL and falling 0.04 g/dL) and at discharge (BrAC below 0.02 g/dL).

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the start of the infusion

  7. Alcohol-induced cognitive/psychomotor impairment as measured by a computerized Simple Reaction Time (SRT)

    A computerized Simple Reaction Time (SRT) test will measure the exact time it takes for a participant to detect a single, predictable stimulus (a star on the screen) and execute a single, predetermined physical response (pressing a mouse button). The primary outcome will be speed (milliseconds). Lower values mean faster responses (a better outcome). Measured at two BrAC windows in each session: baseline (0.00 g/dL) and rising 0.10 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 2 hours after the start of the infusion

  8. Alcohol-induced cognitive/psychomotor impairment as measured by a computerized Digit Symbol Substitution Test (DSST)

    The computerized Digit Symbol Substitution Test (DSST) is a brief timed coding task (90 to 120 seconds) in which participants use a key to pair digits with symbols and produce as many correct matches as possible. The primary outcome of the DSST is the amount of correctly matched symbols and the speed at which matches are made. More correct matches and faster matching mean better performance (a better outcome). Measured at two BrAC windows in each session: baseline (0.00 g/dL) and rising 0.10 g/dL.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 2 hours after the start of the infusion

  9. Monitoring safety and Adverse Events (AEs) measured by the Systematic Assessment for Treatment Emergent Events (SAFTEE)

    The Systematic Assessment for Treatment Emergent Events (SAFTEE) multi-symptom checklist that has been used successfully in the investigators previous studies to assess and monitor any adverse events and possible side effects of study medications. It includes information regarding the severity of any presenting symptoms (0= none, 1= mild, 2= moderate, and 3= severe), as well as the course of action taken by the study staff in response. Any AEs observed by study staff and/or spontaneously reported by the participant will be continuously monitored throughout their enrollment however documentation on the SAFTEE will be completed at four discrete timepoints per test session: pre-infusion, ascending 0.10 g/dL, descending 0.04 g/dL, and pre-discharge (BrAC less than 0.02 g/dL) as well as during the one-week follow-up. Outcomes will be tabulated, and descriptive analyses will be conducted. Dosing conditions will be compared with regards to the frequency and severity of AEs.

    Time frame: Each of two test sessions (at least 48 hours apart): before the infusion (baseline) and up to 6 hours after the infusion; One-week follow-up

  10. Alcohol withdrawal symptoms will be assessed using the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)

    The Clinical Institute Withdrawal Assessment Alcohol Scale Revised (CIWA-AR) is a 10-item instrument used to assess the severity of alcohol withdrawal. Nine items are scored on a 0 to 7 scale while one item (orientation) is rated from 0 to 4. Scores are calculated by summing the ratings of each item with total scores ranging from 0 to 67, with higher scores indicating more severe withdrawal.

    Time frame: Screening; Each of two test sessions: pre-infusion, BrAC less than 0.02 g/dL (pre-discharge); one-week follow-up

  11. Monitoring cardiovascular effects

    To monitor cardiovascular effects vital signs including heart rate and blood pressure will be measured at screening, during the infusion sessions starting at pre-infusion and every 30 minutes until discharge (approximately 6 hours), and during the one-week follow-up to monitor for acute changes.

    Time frame: Screening, Two test sessions [up to 6 hours each], one-week follow-up

07

Study locations

1 site
08

References and documents

Publications

  • De Aquino JP, Sloan ME, Nunes JC, Costa GPA, Katz JL, de Oliveira D, Ra J, Tang VM, Petrakis IL. Alcohol Use Disorder and Chronic Pain: An Overlooked Epidemic. Am J Psychiatry. 2024 May 1;181(5):391-402. doi: 10.1176/appi.ajp.20230886. PubMed 38706339 ↗
  • Hall OT, Rausch J, Entrup P, Lagisetty P, Bryan C, Black L, Moreno J, Gorka S, Phan KL, Clauw DJ. Nociplastic Pain and Pain-Motivated Drinking in Alcohol Use Disorder. J Pain. 2024 Jun;25(6):104467. doi: 10.1016/j.jpain.2024.01.332. Epub 2024 Jan 12. PubMed 38219852 ↗
  • Zambelis T, Karandreas N, Tzavellas E, Kokotis P, Liappas J. Large and small fiber neuropathy in chronic alcohol-dependent subjects. J Peripher Nerv Syst. 2005 Dec;10(4):375-81. doi: 10.1111/j.1085-9489.2005.00050.x. PubMed 16279987 ↗
  • Fernandez A, Graf G, Lasserre A, Daeppen JB, Chu Sin Chung P, Berna C, Suter MR. Somatosensory profiling of patients undergoing alcohol withdrawal: Do neuropathic pain and sensory loss represent a problem? J Peripher Nerv Syst. 2023 Sep;28(3):490-499. doi: 10.1111/jns.12578. Epub 2023 Jul 12. PubMed 37419872 ↗
  • Hall OT, Entrup P, King A, Vilensky M, Bryan CJ, Teater J, Niedermier J, Kaplan CM, Turner JA, Gorka S, Harte SE, Williams DA, Clauw DJ. Central sensitization in alcohol use disorder: correlates of pain, addiction and health-related quality of life. J Addict Dis. 2025 Jan-Mar;43(1):32-43. doi: 10.1080/10550887.2023.2237396. Epub 2023 Jul 22. PubMed 37480264 ↗
  • Apkarian AV, Neugebauer V, Koob G, Edwards S, Levine JD, Ferrari L, Egli M, Regunathan S. Neural mechanisms of pain and alcohol dependence. Pharmacol Biochem Behav. 2013 Nov;112:34-41. doi: 10.1016/j.pbb.2013.09.008. Epub 2013 Oct 2. PubMed 24095683 ↗
  • Egli M, Koob GF, Edwards S. Alcohol dependence as a chronic pain disorder. Neurosci Biobehav Rev. 2012 Nov;36(10):2179-92. doi: 10.1016/j.neubiorev.2012.07.010. Epub 2012 Sep 11. PubMed 22975446 ↗
  • Witkiewitz K, Vowles KE. Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review. Alcohol Clin Exp Res. 2018 Mar;42(3):478-488. doi: 10.1111/acer.13594. Epub 2018 Feb 6. PubMed 29314075 ↗
  • Nieto SJ, Green R, Grodin EN, Cahill CM, Ray LA. Pain catastrophizing predicts alcohol craving in heavy drinkers independent of pain intensity. Drug Alcohol Depend. 2021 Jan 1;218:108368. doi: 10.1016/j.drugalcdep.2020.108368. Epub 2020 Oct 20. PubMed 33143942 ↗
  • Brennan PL, Schutte KK, Moos RH. Pain and use of alcohol to manage pain: prevalence and 3-year outcomes among older problem and non-problem drinkers. Addiction. 2005 Jun;100(6):777-86. doi: 10.1111/j.1360-0443.2005.01074.x. PubMed 15918808 ↗
  • Boissoneault J, Lewis B, Nixon SJ. Characterizing chronic pain and alcohol use trajectory among treatment-seeking alcoholics. Alcohol. 2019 Mar;75:47-54. doi: 10.1016/j.alcohol.2018.05.009. Epub 2018 May 25. PubMed 30359794 ↗
  • Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD. 2010 National and State Costs of Excessive Alcohol Consumption. Am J Prev Med. 2015 Nov;49(5):e73-e79. doi: 10.1016/j.amepre.2015.05.031. Epub 2015 Oct 1. PubMed 26477807 ↗
  • Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012 Aug;13(8):715-24. doi: 10.1016/j.jpain.2012.03.009. Epub 2012 May 16. PubMed 22607834 ↗
  • GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17. PubMed 38642570 ↗
  • Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009 Apr 28;6(4):e1000058. doi: 10.1371/journal.pmed.1000058. Epub 2009 Apr 28. PubMed 19399161 ↗
  • Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC, Borges GL, Bromet EJ, Demytteneare K, de Girolamo G, de Graaf R, Gureje O, Lepine JP, Haro JM, Levinson D, Oakley Browne MA, Posada-Villa J, Seedat S, Watanabe M. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008 Oct;9(10):883-91. doi: 10.1016/j.jpain.2008.05.005. Epub 2008 Jul 7. PubMed 18602869 ↗
  • Vitus D, Williams MK, Rizk M, Neubert JK, Robinson M, Boissoneault J. Analgesic effects of alcohol in adults with chronic jaw pain. Alcohol Clin Exp Res. 2022 Aug;46(8):1515-1524. doi: 10.1111/acer.14883. Epub 2022 Aug 22. PubMed 35989585 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Apr 2031, 50 months later.

Of 24 phase 2 interventional studies under Alcohol Drinking, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 62. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 17, 2026
StartEst.
Feb 2027
Primary completionEst.
Apr 2031
CompletionEst.
Jul 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941895
Lead sponsor
Yale University
Responsible party
Joao De Aquino (Assistant Professor of Psychiatry, Yale University) — Principal investigator
First posted
Nov 17, 2026
Start date
Feb 2027 (estimated)
Primary completion
Apr 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Julia Meyerovich
Contact
julia.meyerovich@yale.edu
203-932-5711 ext. 14805
Joao P. De Aquino, M.D.
Contact
joao.deaquinolima@yale.edu
203-932-5711 ext. 12916
Joao P. De Aquino, M.D.
principal investigator · Yale University
Ismene L. Petrakis, M.D.
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion